Clinical Biomarker Services
Accredited biomarker testing and bioinformatics services for oncology and translational research.
Receive your quote directly from the manufacturer.
Crown Bioscience delivers end-to-end clinical biomarker services designed to generate reliable, clinically relevant data across all phases of drug development. With a global network of CAP- and CLIA-accredited laboratories in the US, Europe, and Asia, we provide harmonized workflows that meet the highest scientific and regulatory standards.
Our expertise spans tissue-based methods, spatial biology, multiplex immunoassays, advanced flow cytometry, and multi-omics platforms, supported by robust bioinformatics and regulatory-compliant reporting. These capabilities enable researchers to identify, validate, and monitor biomarkers that drive translational insights and clinical impact.
Key features include:
- Tissue & Digital Pathology: IHC, IF, in situ hybridization, tissue microarrays, and AI-driven image analysis.
- Spatial & Multi-Omics Technologies: Including NanoString GeoMx DSP, 10x Genomics, and proteomic profiling.
- Flow Cytometry: High-parameter immunophenotyping and rare cell detection.
- Bioanalytical Assays: ELISA, MSD multiplex, LC/MS, and custom assay development.
- Bioinformatics: Integrated pipelines for genomics, transcriptomics, proteomics, and translational data interpretation.
- Global Compliance: CAP, CLIA, GCLP, and ISO-certified facilities ensuring data integrity and reproducibility.
By integrating advanced technology platforms with deep biomarker expertise, Crown Bioscience helps pharma and biotech teams reduce attrition, accelerate timelines, and make confident translational decisions.
